ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Early-Stage Breast Carcinoma
Interventions: DRUG: ME-344|DRUG: Bevacizumab|OTHER: Normal saline
Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators: Fundacion CRIS de Investigación para Vencer el Cáncer